120 related articles for article (PubMed ID: 30587910)
41. Corrigendum.
Sun XH; Yu HZ; Yang MM; Yang YM; Dang ZM
J Cachexia Sarcopenia Muscle; 2015 Jun; 6(2):192. PubMed ID: 26140254
[TBL] [Abstract][Full Text] [Related]
42. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
[TBL] [Abstract][Full Text] [Related]
43. Erratum: Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.
Saudi J Med Med Sci; 2021; 9(2):199. PubMed ID: 34084113
[TBL] [Abstract][Full Text] [Related]
44. Erratum: Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations [Corrigendum].
Neuropsychiatr Dis Treat; 2019; 15():655. PubMed ID: 30880990
[TBL] [Abstract][Full Text] [Related]
45. Erratum: Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum].
Drug Healthc Patient Saf; 2018; 10():67-68. PubMed ID: 30038524
[TBL] [Abstract][Full Text] [Related]
46. Erratum: Efficacy and effectiveness trials have different goals, use different tools, and generate different messages [Corrigendum].
Pragmat Obs Res; 2016; 7():1. PubMed ID: 27801423
[TBL] [Abstract][Full Text] [Related]
47. Erratum: Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE [Corrigendum].
Int J Chron Obstruct Pulmon Dis; 2016; 11():1031-1033. PubMed ID: 27274224
[TBL] [Abstract][Full Text] [Related]
48. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
[TBL] [Abstract][Full Text] [Related]
49. Erratum: User assessment of Norditropin NordiFlex®, a new prefilled growth hormone pen: a Phase IV multicenter prospective study [Corrigendum].
Patient Prefer Adherence; 2013; 7():803. PubMed ID: 23983458
[TBL] [Abstract][Full Text] [Related]
50. Erratum: Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [Corrigendum].
J Pain Res; 2018; 11():213. PubMed ID: 29406534
[TBL] [Abstract][Full Text] [Related]
51. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.
Amparo F; Dastjerdi MH; Okanobo A; Ferrari G; Smaga L; Hamrah P; Jurkunas U; Schaumberg DA; Dana R
JAMA Ophthalmol; 2013 Jun; 131(6):715-723. PubMed ID: 23599118
[TBL] [Abstract][Full Text] [Related]
52. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
[TBL] [Abstract][Full Text] [Related]
53. Erratum: Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum].
Clin Ophthalmol; 2017; 11():355. PubMed ID: 28243059
[TBL] [Abstract][Full Text] [Related]
54. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
[TBL] [Abstract][Full Text] [Related]
55. Erratum: Comparison of the acute-phase response after laparoscopic versus open aortobifemoral bypass surgery: a substudy of a randomized controlled trial [Erratum].
Vasc Health Risk Manag; 2017; 13():215. PubMed ID: 28670131
[TBL] [Abstract][Full Text] [Related]
56. Erratum: Amino acid management of Parkinson's disease: a case study [Corrigendum].
Int J Gen Med; 2016; 9():205. PubMed ID: 27354822
[TBL] [Abstract][Full Text] [Related]
57. Erratum: Drug prescription appropriateness in the elderly: an Italian study [Corrigendum].
Clin Interv Aging; 2017; 12():2131. PubMed ID: 29290683
[TBL] [Abstract][Full Text] [Related]
58. Corrigendum: A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek.
Shin DM; Lee J; Noh H; Jang D; Oh SJ; Park JH; Lee JH
Ann Dermatol; 2023 Feb; 35(1):88. PubMed ID: 36750469
[TBL] [Abstract][Full Text] [Related]
59. Erratum: Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids [Corrigendum].
J Pain Res; 2015; 8():807. PubMed ID: 26664153
[TBL] [Abstract][Full Text] [Related]
60. Erratum: Patients' beliefs about adherence to oral antidiabetic treatment: a qualitative study [Corrigendum].
Patient Prefer Adherence; 2017; 11():1709. PubMed ID: 29042754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
